IL318205A - Preparation methods for a highly concentrated pd1 antibody solution by ultrafiltration/diafiltration (uf/df) - Google Patents

Preparation methods for a highly concentrated pd1 antibody solution by ultrafiltration/diafiltration (uf/df)

Info

Publication number
IL318205A
IL318205A IL318205A IL31820525A IL318205A IL 318205 A IL318205 A IL 318205A IL 318205 A IL318205 A IL 318205A IL 31820525 A IL31820525 A IL 31820525A IL 318205 A IL318205 A IL 318205A
Authority
IL
Israel
Prior art keywords
diafiltration
ultrafiltration
preparation methods
highly concentrated
antibody solution
Prior art date
Application number
IL318205A
Other languages
Hebrew (he)
Inventor
Yu Ji
Xuening Li
Jiankun Ding
Bo Qiu
Original Assignee
Beigene Switzerland Gmbh
Yu Ji
Xuening Li
Jiankun Ding
Bo Qiu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Switzerland Gmbh, Yu Ji, Xuening Li, Jiankun Ding, Bo Qiu filed Critical Beigene Switzerland Gmbh
Publication of IL318205A publication Critical patent/IL318205A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/22—Controlling or regulating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/58—Multistep processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
    • B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/14—Pressure control
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2317/00—Membrane module arrangements within a plant or an apparatus
    • B01D2317/02—Elements in series
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2325/00—Details relating to properties of membranes
    • B01D2325/34—Molecular weight or degree of polymerisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Water Supply & Treatment (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL318205A 2022-07-12 2023-07-07 Preparation methods for a highly concentrated pd1 antibody solution by ultrafiltration/diafiltration (uf/df) IL318205A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022105070 2022-07-12
CN2023074867 2023-02-08
PCT/CN2023/106294 WO2024012364A1 (en) 2022-07-12 2023-07-07 Preparation methods for a highly concentrated pd1 antibody solution by ultrafiltration/diafiltration (uf/df)

Publications (1)

Publication Number Publication Date
IL318205A true IL318205A (en) 2025-03-01

Family

ID=89535572

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318205A IL318205A (en) 2022-07-12 2023-07-07 Preparation methods for a highly concentrated pd1 antibody solution by ultrafiltration/diafiltration (uf/df)

Country Status (9)

Country Link
US (1) US20250197445A1 (en)
EP (1) EP4554979A4 (en)
JP (1) JP2025522984A (en)
KR (1) KR20250036190A (en)
AU (1) AU2023306365A1 (en)
CA (1) CA3261698A1 (en)
IL (1) IL318205A (en)
MX (1) MX2025000463A (en)
WO (1) WO2024012364A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250288957A1 (en) * 2024-03-14 2025-09-18 Amgen Inc. Intensified ultrafiltration/diafiltration processes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP5432137B2 (en) * 2007-07-17 2014-03-05 エフ.ホフマン−ラ ロシュ アーゲー Variable tangential flow filtration
CN101874040A (en) * 2007-11-29 2010-10-27 弗·哈夫曼-拉罗切有限公司 immunoglobulin aggregates
SMT202300039T1 (en) * 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
CN104231075B (en) * 2014-09-02 2017-03-22 江西博雅生物制药股份有限公司 Preparation process of human hepatitis B immunoglobulin
CN104193822B (en) * 2014-09-09 2017-05-24 江西博雅生物制药股份有限公司 Process for preparing rabies human immune globulin
CN105085610A (en) * 2015-08-17 2015-11-25 张卫民 Graded secondary ultrafiltration purification method for antibacterial peptide
KR102154952B1 (en) * 2020-02-21 2020-09-10 프레스티지바이오로직스 주식회사 Non-Protein A Purification of Adalimumab
CN114014929B (en) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 Preparation method of anti-human interleukin-33 monoclonal antibody concentrated solution

Also Published As

Publication number Publication date
US20250197445A1 (en) 2025-06-19
JP2025522984A (en) 2025-07-17
WO2024012364A1 (en) 2024-01-18
MX2025000463A (en) 2025-05-02
KR20250036190A (en) 2025-03-13
EP4554979A4 (en) 2026-08-19
EP4554979A1 (en) 2025-05-21
AU2023306365A1 (en) 2025-02-13
CA3261698A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
CA3261698A1 (en) Preparation methods for a highly concentrated pd1 antibody solution by ultrafiltration/diafiltration (uf/df)
MY182178A (en) Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
MX2018003298A (en) Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method.
MX2020013975A (en) Production and separation of milk fractions with forward osmosis.
EP4012043A4 (en) METHOD FOR ISOLATING BIO-NANOPARTICLES USING AQUEOUS TWO-PHASE SYSTEM SEPARATION COMPOSITION
PL3763222T3 (en) Method for obtaining a concentrated protein rich phase from residues of bioethanol production
EP4282856A4 (en) Method for preparing taurine
ZA202206855B (en) Method for preparing composite membrane by ultrasonic spray
AU2024381971A1 (en) Process for producing a concentrate
EP4251184A4 (en) A process for preparing a pharmaceutical preparation
BR112022012463A2 (en) METHOD TO MAKE A MILK COMPOSITION AND MILK COMPOSITION
PL3996520T3 (en) Concentrate for producing a wetting solution
EP4273186A4 (en) Method for preparing polyphenylene oxide
PL4009808T3 (en) Concentrate for preparing a drinking solution
EP4177251A4 (en) Method for preparing isoxazoline-containing uracil compound intermediates
HK40104585A (en) Method for the preparation of a serving of a reconstituted beverage
AU2023903681A0 (en) Process for producing a concentrate
CA3284576A1 (en) A process for preparation of l-glufosinate or salts thereof
CA3283465A1 (en) A process for the preparation l-glufosinate or salts thereof
IL326888A (en) Ultrafiltration/diafiltration purification methods
EP3953320A4 (en) Method for preparing glycolic acid
CA3282744A1 (en) A process for preparing l-glufosinate from cyanhydrine or cyanhydrine derivatives
CA3302675A1 (en) Method for preparing coffee
CA3289592A1 (en) Methods for preparing (-)-epicatechin
ZA202210343B (en) A method for preparing sechium edule extract for reversing neurotoxicity of lead